Fallopian tube cancer is an acquired malignancy. No inherited causative gene has been identified for the disease in this data set. The molecular events contributing to tumor development are an area of ongoing research in the broader context of gynecologic cancers.

Diagnosis typically involves imaging studies, pathologic examination of tumor tissue, and surgical evaluation. Fallopian tube cancer is often grouped with ovarian and peritoneal cancers in clinical evaluation and management due to shared biology and treatment approaches. Gynecologic oncology expertise is central to diagnosis and staging.

Olaparib (LYNPARZA), a PARP inhibitor, is FDA-approved for fallopian tube cancer (approved August 2017) and represents a targeted treatment option. Treatment decisions are guided by tumor subtype, disease extent, and clinical context, and typically involve gynecologic oncology specialists. Clinical research in this area often includes fallopian tube cancer within broader gynecologic cancer trials.

Prognosis depends on tumor subtype, histology, and stage at diagnosis. Like other rare gynecologic malignancies, outcomes vary considerably. Multidisciplinary oncologic care is recommended.

Fallopian tube cancer is included in ongoing clinical trials evaluating novel therapies for gynecologic cancers. Published research encompasses 63 classified studies, with case reports and case series as the dominant study type. Biomarker research and reviews contribute to the growing evidence base.